Floatz logo

34 assets in High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit

Therapeutic assets addressing High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Rituximab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Yazeed SawalhaP2B (61)
Cyclophosphamide
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Mayo ClinicP2B (58)
Dexasone
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2B (58)
Etoposide
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
David Bond, MDP2B (58)
Ibrutinib
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2B (58)
Prednisone
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2B (58)
Venetoclax
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2B (58)
(+)-Vincristine
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Patrick C. Johnson, MDP2B (58)
Acalabrutinib
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Patrick C. Johnson, MDP2CCC (53)
Axicabtagene Ciloleucel
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
City of Hope Medical CenterP2CCC (53)
Bortezomib
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Rutgers, The State University of New JerseyP2CCC (53)
Carboplatin
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
David Bond, MDP2CCC (53)
Clofarabine
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
M.D. Anderson Cancer CenterP2CCC (53)
Humax-Cd20
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
M.D. Anderson Cancer CenterP2CCC (53)
Isocyclophosphamide
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
David Bond, MDP2CCC (53)
Jcar-017 Cd19-Specific Chimeric Antigen Receptor
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Patrick C. Johnson, MDP2CCC (53)
Lenalidomide
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2CCC (53)
Obinutuzumab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2CCC (53)
Ontorpacept
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Mayo ClinicP2CCC (53)
Pegfilgrastim
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
M.D. Anderson Cancer CenterP2CCC (53)
Pembrolizumab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Mayo ClinicP2CCC (53)
Selinexor
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Zhejiang Cancer HospitalP2CCC (53)
Sepantronium
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Cothera Bioscience, IncP2CCC (53)
Tafasitamab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
David Bond, MDP2CCC (53)
Cytarabine
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Yazeed SawalhaP1/2CCC (50)
Idp-121
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
IDP Discovery Pharma S.L.P1/2CCC (48)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Mayo ClinicP2CC (45)
Epcoritamab
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Yazeed SawalhaP1/2CC (45)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
National Cancer Institute (NCI)P2CC (44)
Camustine
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Fred Hutchinson Cancer CenterP1CC (41)
Loncastuximab Tesirine
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Fred Hutchinson Cancer CenterP1CC (41)
Melphalan
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Fred Hutchinson Cancer CenterP1CC (41)
Tegavivint
High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit
Lapo AlinariP1CC (41)